A platform capable of isolating and analyzing EECs has been set up by NGM to recognize novel secreted peptide hormones that are potentially linked to the metabolic effects of bariatric surgery.
The hormones can also serve as potential targets for the treatment of metabolic diseases.
Based on the discovered EEC hormones, both companies will collectively develop first-in-class peptide and antibody drug candidates.
MedImmune cardiovascular and metabolic disease innovative medicines unit head Cristina Rondinone said that the company anticipates that hormones in the gastrointestinal tract can play an important role in resolving diabetes after bariatric surgery.
"Through NGM’s innovative research in metabolic disease, we believe our collaboration could lead to potential innovative medicines for diabetes and obesity that will make a difference in patients’ lives," Rondinone added.
As per terms of the agreement, NGM will receive an upfront payment and research funding from MedImmune during the period of collaboration.
It will also receive various payments and royalties on worldwide product sales after obtaining certain development, regulatory and commercial milestones.
MedImmune will be provided with the alternatives to license in these EEC targets, and will be responsible for the global development, manufacture and commercialization of compounds resulting from the collaboration.